

60 documenti

search details

Deandreis D[Author] OR Ceci, Francesco[Full Author Name] AND  
("2016/01/01"[PDAT] : "2019/12/31"[PDAT])

1: Ceci F, Bianchi L, Borghesi M, Polverari G, Farolfi A, Briganti A, Schiavina R, Brunocilla E, Castellucci P, Fanti S. Prediction nomogram for (68)Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. *Eur J Nucl Med Mol Imaging*. 2019 Sep 6. doi: 10.1007/s00259-019-04505-2. [Epub ahead of print] PubMed PMID: 31492993.

2: Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. *Lancet Oncol*. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. PubMed PMID: 31375469.

3: Finessi M, Bisi G, Deandreis D. Hyperglycemia and 18F-FDG PET/CT, issues and problem solving: a literature review. *Acta Diabetol*. 2019 Jul 15. doi: 10.1007/s00592-019-01385-8. [Epub ahead of print] Review. PubMed PMID: 31304560.

4: Terroir M, Grimaldi S, Hartl D, Leboulleux S, Deandreis D. Parathyroid Glands Hyperplasias Mimicking Medullary Thyroid Carcinoma Metastatic Lymph Nodes on 18F-DOPA PET/CT. *Clin Nucl Med*. 2019 Aug;44(8):e497-e498. doi: 10.1097/RLU.0000000000002633. PubMed PMID: 31274634.

5: Terroir M, Grimaldi S, Hartl D, Leboulleux S, Deandreis D. Parathyroid Glands Hyperplasias Mimicking Medullary Thyroid Carcinoma Metastatic Lymph Nodes on

18F-DOPA PET/CT. Clin Nucl Med. 2019 Jun 1. doi: 10.1097/RLU.0000000000002633.  
[Epub ahead of print] PubMed PMID: 31162251.

6: Bianchi L, Schiavina R, Borghesi M, Ceci F, Angiolini A, Chessa F, Droghetti M, Bertaccini A, Manferrari F, Marcelli E, Cochetti G, Porreca A, Castellucci P, Fanti S, Brunocilla E. How does (68) Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery? Int J Urol. 2019 Aug;26(8):804-811. doi: 10.1111/iju.14012. Epub 2019 May 13. PubMed PMID: 31083784.

7: Morris MJ, Lorient Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 Jun; 114:107-116. doi: 10.1016/j.ejca.2019.04.007. Epub 2019 May 11. PubMed PMID: 31082669.

8: Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, Coriat R, Hindie E, Taieb D, Tabarin A, Girard A, Grellier JF, Brenot-Rossi I, Groheux D, Rousseau C, Deandreis D, Alberini JL, Bodet-Milin C, Itti E, Casasnovas O, Kraeber-Bodere F, Moreau P, Philip A, Balleyguier C, Lucian A, Cachin F. [Update of the recommendations of good clinical practice for the use of PET in oncology]. Bull Cancer. 2019 Mar;106(3):262-274. doi: 10.1016/j.bulcan.2019.01.002. Epub 2019 Jan 23. French. PubMed PMID: 30683308.

9: Nicolotti DG, Finessi M, Guarneri A, Pilati E, Giunta F, Deandreis D. Impact of functional imaging in prostate cancer: a clinical point of view. Q J Nucl Med Mol Imaging. 2019 Mar;63(1):1-6. doi: 10.23736/S1824-4785.19.03160-1. Epub 2019

Jan 15. PubMed PMID: 30644307.

10: Polverari G, Ceci F, Calderoni L, Cervati V, Farolfi A, Castellucci P, Fanti S. Male Breast Cancer Detected by (68)Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. Clin Genitourin Cancer. 2019 Apr;17(2):154-156. doi: 10.1016/j.clgc.2018.11.020. Epub 2018 Dec 4. PubMed PMID: 30587404.

11: Liberini V, Nicolotti DG, Maccario M, Finessi M, Deandreis D. 68Ga-DOTA-TOC PET/CT of von Hippel-Lindau Disease. Clin Nucl Med. 2019 Feb;44(2):125-126. doi: 10.1097/RLU.0000000000002395. PubMed PMID: 30516678.

12: Angelini A, Castellucci P, Ceci F. Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders. PET Clin. 2019 Jan;14(1):183-191. doi: 10.1016/j.cpet.2018.08.012. Epub 2018 Oct 24. Review. PubMed PMID: 30420219.

13: Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S. (68)Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):31-39. doi: 10.1007/s00259-018-4189-7. Epub 2018 Oct 22. PubMed PMID: 30350010.

14: Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by (68)Ga-PSMA-11 PET/CT. Clin Genitourin Cancer. 2019 Feb;17(1):e53-e55. doi: 10.1016/j.clgc.2018.09.003. Epub 2018 Sep 7. PubMed PMID: 30293922.

15: Schiavina R, Chessa F, Borghesi M, Gaudiano C, Bianchi L, Corcioni B,

Castellucci P, Ceci F, Ceravolo I, Barchetti G, Del Monte M, Campa R, Catalano C, Panebianco V, Nanni C, Fanti S, Minervini A, Porreca A, Brunocilla E.

State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. *Int J Urol*. 2019 Jan;26(1):18-30.

doi:

10.1111/iju.13797. Epub 2018 Sep 20. Review. PubMed PMID: 30238516.

16: Ceci F, Polverari G, Calais J, Castellucci P. The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals. *Eur J Nucl Med Mol Imaging*. 2018 Dec;45(13):2253-2255. doi: 10.1007/s00259-018-4162-5. PubMed

PMID: 30232540.

17: Castellucci P, Ceci F, Fanti S. Imaging of Prostate Cancer Using (11)C-Choline PET/Computed Tomography. *Urol Clin North Am*. 2018 Aug;45(3):481-487. doi: 10.1016/j.ucl.2018.03.007. Review. PubMed PMID: 30031467.

18: Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S. (68)Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. *Eur J Nucl Med Mol Imaging*. 2019 Jan;46(1):11-19. doi: 10.1007/s00259-018-4066-4. Epub 2018 Jun 15.

PubMed PMID: 29905907.

19: Schiavina R, Bianchi L, Mineo Bianchi F, Borghesi M, Pultrone CV, Dababneh H, Castellucci P, Ceci F, Nanni C, Gaudio C, Fiorentino M, Porreca A, Chessa F, Minervini A, Fanti S, Brunocilla E. Preoperative Staging With (11)C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer.

*Clin Genitourin Cancer*. 2018 Aug;16(4):305-312.e1. doi: 10.1016/j.clgc.2018.05.010. Epub 2018 May 30. PubMed PMID: 29859737.

20: Schlumberger M, Leboulleux S, Catargi B, Deandreis D, Zerdoud S, Bardet S, Rusu D, Godbert Y, Buffet C, Schvartz C, Vera P, Morel O, Benisvy D,

Bournaud C,  
Toubert ME, Kelly A, Benhamou E, Borget I. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. *Lancet Diabetes Endocrinol.* 2018 Aug;6(8):618-626. doi: 10.1016/S2213-8587(18)30113-X. Epub 2018 May 26. PubMed PMID: 29807824.

21: Fodor A, Lancia A, Ceci F, Picchio M, Hoyer M, Jereczek-Fossa BA, Ost P, Castellucci P, Incerti E, Di Muzio N, Ingrosso G. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row. *World J Urol.* 2018 May 11. doi: 10.1007/s00345-018-2322-7. [Epub ahead of print] PubMed PMID: 29752513.

22: Czernin J, Ceci F. Aetna and (68)Ga-DOTATATE: A Sequel to "The Injustice of Being Judged by the Errors of Others". *J Nucl Med.* 2018 May;59(5):721-722. PubMed PMID: 29717082.

23: Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, Berdelou A, Hadoux J, Hescot S, Remy H, Baudin E, Schlumberger M, Deandreis D. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of (18)F-Fluorocholine PET/CT. *Eur J Nucl Med Mol Imaging.* 2018 Sep;45(10):1772-1780. doi: 10.1007/s00259-018-4018-z. Epub 2018 Apr 22. PubMed PMID: 29680989.

24: Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. Potential Impact of (68)Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. *J Nucl Med.* 2018 Nov;59(11):1714-1721. doi: 10.2967/jnumed.118.209387. Epub 2018 Apr 13. PubMed PMID: 29653978; PubMed Central PMCID: PMC6225538.

25: Farolfi A, Ceci F, Graziani T, Lambertini A, Cervati V, Basilico GL, Biraghi T, Briganti A, Castellucci P, Fanti S. Incidental Detection of Basaloid Thymic Carcinoma With (68)Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate Cancer. Clin Genitourin Cancer. 2018 Jun;16(3):e497-e499. doi: 10.1016/j.clgc.2018.02.019. Epub 2018 Feb 23. PubMed PMID: 29550202.

26: Ceci F, Castellucci P, Fanti S. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. Q J Nucl Med Mol Imaging. 2019 Mar;63(1):7-18. doi: 10.23736/S1824-4785.18.03059-5. Epub 2018 Mar 8. Review. PubMed PMID: 29521482.

27: Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. Reply: Comparison of (68)Ga-PSMA-11 and (18)F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way. J Nucl Med. 2018 May;59(5):861. doi: 10.2967/jnumed.118.209965. Epub 2018 Mar 1. PubMed PMID: 29496985.

28: Finessi M, Nicolotti DG, Bisi G, Deandreis D. Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: Are There Unsuspected Confounders? J Nucl Med. 2018 Apr; 59(4):713. doi: 10.2967/jnumed.117.205856. Epub 2018 Jan 11. PubMed PMID: 29326359.

29: Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. Comparison of (68)Ga-PSMA-11 and (18)F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. J Nucl Med. 2018 May;59(5):789-794. doi: 10.2967/jnumed.117.203257. Epub 2017 Dec 14. PubMed PMID: 29242404.

30: Ceci F, Fendler W, Eiber M. A New Type of Prostate Cancer Imaging: Will (64)CuCl(2) PET/CT Flourish or Vanish? J Nucl Med. 2018 Mar;59(3): 442-443. doi: 10.2967/jnumed.117.199885. Epub 2017 Dec 14. PubMed PMID: 29242402.

31: Finessi M, Bellù M, Giunta FP, Veltri A, Deandreis D. Interventional locoregional treatment and metabolic response: advantages of using PET/CT in the evaluation of response to treatment. *Q J Nucl Med Mol Imaging*. 2018 Jun;62(2):165–184. doi: 10.23736/S1824–4785.17.03037–0. Epub 2017 Nov 22. Review. PubMed PMID: 29166753.

32: Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt–Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. (68)Ga–PSMA–11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. *J Nucl Med*. 2018 Feb;59(2):230–237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9. PubMed PMID: 29123013; PubMed Central PMCID: PMC5807533.

33: Garbaccio V, Menga M, Mensa G, Passera R, Galati A, Codegone A, Finessi M, Pilati E, Deandreis D, Pellerito RE. Impact of Radioguided Occult Lesion Localization (ROLL) in the management of cervical recurrences from differentiated thyroid cancer. *Q J Nucl Med Mol Imaging*. 2017 Sep 20. doi: 10.23736/S1824–4785.17.03027–8. [Epub ahead of print] PubMed PMID: 28933526.

34: Hadoux J, Terroir M, Leboulleux S, Deschamps F, Al Ghuzlan A, Hescot S, Tselikas L, Borget I, Caramella C, DÈandrÈis D, Goere D, De Baere T, Schlumberger M, Baudin E. Interferon–alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients. *Horm Cancer*. 2017 Dec; 8(5–6):330–337. doi: 10.1007/s12672–017–0303–8. Epub 2017 Jul 26. PubMed PMID: 28748315.

35: Ceci F, Castellucci P, Cerci JJ, Fanti S. New aspects of molecular imaging in prostate cancer. *Methods*. 2017 Nov 1;130:36–41. doi: 10.1016/j.ymeth.2017.07.009. Epub 2017 Jul 13. Review. PubMed PMID: 28711565.

36: Ceci F, Herrmann K, Hadaschik B, Castellucci P, Fanti S. Therapy assessment in prostate cancer using choline and PSMA PET/CT. *Eur J Nucl Med Mol Imaging*. 2017 Aug;44(Suppl 1):78–83. doi: 10.1007/s00259-017-3723-3. Epub 2017 May 25. Review. PubMed PMID: 28540419.

37: Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, Hofman MS, Eiber M, Schwarzenbock S, Castellucci P, Bellisario C, Chauvie S, Bergesio F, Emmett L, Haberkorn U, Virgolini I, Schwaiger M, Hicks RJ, Krause BJ, Chiti A. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. *Eur J Nucl Med Mol Imaging*. 2017 Sep; 44(10):1622–1635. doi: 10.1007/s00259-017-3725-1. Epub 2017 May 23. PubMed PMID: 28536833.

38: Deandreis D. Reply: Fixed 3.7-GBq (131)I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History. *J Nucl Med*. 2017 Sep; 58(9):1531. doi: 10.2967/jnumed.117.193185. Epub 2017 Apr 27. PubMed PMID: 28450565.

39: Angelini A, Ceci F, Castellucci P, Graziani T, Polverari G, Trovarelli G, Palmerini E, Ferrari S, Fanti S, Ruggieri P. The role of (18)F-FDG PET/CT in the detection of osteosarcoma recurrence. *Eur J Nucl Med Mol Imaging*. 2017 Sep;44(10):1712–1720. doi: 10.1007/s00259-017-3698-0. Epub 2017 Apr 12. PubMed PMID: 28405727.

40: Lamartina L, Borget I, Mirghani H, Al Ghuzlan A, Berdelou A, Bidault F, Deandreis D, Baudin E, Travaglini JP, Schlumberger M, Hartl DM, Leboulleux S. Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors. *J Clin Endocrinol Metab*. 2017 Mar 1;102(3):1020–1031. doi: 10.1210/nc.2016-3284. PubMed PMID: 28359102.

41: Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S,



Giesel F,  
Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Sch<sup>^</sup>der H,  
Sunderland J,  
Wan S, Wester HJ, Fanti S, Herrmann K. (68)Ga-PSMA PET/CT: Joint  
EANM and SNMMI  
procedure guideline for prostate cancer imaging: version 1.0. Eur J  
Nucl Med Mol  
Imaging. 2017 Jun;44(6):1014-1024. doi: 10.1007/s00259-017-3670-z.  
PubMed PMID:  
28283702.

42: Castellucci P, Ceci F, Fanti S. Imaging of Prostate Cancer Using  
(11)C-Choline PET/Computed Tomography. PET Clin. 2017 Apr;12(2):  
137-143. doi:  
10.1016/j.cpet.2016.11.002. Epub 2017 Jan 9. Review. PubMed PMID:  
28267448.

43: Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A,  
Leboulleux S,  
D'Èand'Èis D, Hadoux J, Ducreux M, Duvillard P, Adam J, Scoazec JY,  
Baudin E,  
Planchard D. Antitumour activity of somatostatin analogues in  
sporadic,  
progressive, metastatic pulmonary carcinoids. Eur J Cancer. 2017  
Apr;75:259-267.  
doi: 10.1016/j.ejca.2016.11.034. Epub 2017 Feb 27. PubMed PMID:  
28242503.

44: Deandreis D, Schlumberger M, Tuttle RM. Reply: Comparison of  
Empiric Versus  
Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. J  
Nucl Med.  
2017 May;58(5):863-864. doi: 10.2967/jnumed.117.190496. Epub 2017  
Feb 23. PubMed  
PMID: 28232612.

45: Polverari G, Ceci F, Graziani T, Cozzarini C, Castellucci P,  
Fanti S. A Rare  
Case of Epididymal Metastasis After Radical Prostatectomy Detected  
by 68Ga-PSMA  
PET/CT. Clin Genitourin Cancer. 2017 Jun;15(3):e525-e527. doi:  
10.1016/j.clgc.2016.12.011. Epub 2016 Dec 22. PubMed PMID: 28065536.

46: Dromain C, D'Èand'Èis D, Scoazec JY, Goere D, Ducreux M, Baudin  
E, Tselikas L.  
Imaging of neuroendocrine tumors of the pancreas. Diagn Interv  
Imaging. 2016  
Dec;97(12):1241-1257. doi: 10.1016/j.diii.2016.07.012. Epub 2016 Nov  
18. Review.

PubMed PMID: 27876341.

47: Ceci F, Fiorentino M, Castellucci P, Fanti S. Molecular Imaging and Precision Medicine in Prostate Cancer. *PET Clin.* 2017 Jan;12(1):83–92. doi: 10.1016/j.cpet.2016.08.004. Epub 2016 Sep 9. Review. PubMed PMID: 27863569.

48: Terroir M, Borget I, Bidault F, Ricard M, Deschamps F, Hartl D, Tselikas L, Dercle L, Lumbroso J, Baudin E, Berdelou A, Deandreis D, Schlumberger M, Leboulleux S. The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging.* 2017 Apr;44(4):638–646. doi: 10.1007/s00259-016-3551-x. Epub 2016 Oct 29. PubMed PMID: 27796544.

49: Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, Larson S, Fagin JA, Schlumberger M, Tuttle RM. Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. *J Nucl Med.* 2017 May;58(5):717–722. doi: 10.2967/jnumed.116.179606. Epub 2016 Oct 13. PubMed PMID: 27738010.

50: Ceci F, Castellucci P, Mapelli P, Incerti E, Picchio M, Fanti S. Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. *J Nucl Med.* 2016 Oct;57(Suppl 3):49S–54S. Review. PubMed PMID: 27694172.

51: Mapelli P, Incerti E, Ceci F, Castellucci P, Fanti S, Picchio M. 11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. *J Nucl Med.* 2016 Oct;57(Suppl 3):43S–48S. Review. PubMed PMID: 27694171.

52: Ceci F, Castellucci P, Nanni C, Fanti S. PET/CT imaging for evaluating

response to therapy in castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2103–2104. PubMed PMID: 27557847.

53: Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM, Lodi F, Morganti AG, Ardizzoni A, Schiavina R, Fanti S. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1971–9. doi: 10.1007/s00259-016-3428-z. Epub 2016 Jun 8. PubMed PMID: 27277279.

54: Lamartina L, Deandreis D, Durante C, Filetti S. ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. Eur J Endocrinol. 2016 Nov;175(5):R185–202. doi: 10.1530/EJE-16-0088. Epub 2016 Jun 1. Review. PubMed PMID: 27252484.

55: Lamartina L, Ippolito S, Danis M, Bidault F, Borget I, Berdelou A, Al Ghuzlan A, Hartl D, Blanchard P, Terroir M, Deandreis D, Schlumberger M, Baudin E, Leboulleux S. Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer. J Clin Endocrinol Metab. 2016 Jul;101(7):2733–41. doi: 10.1210/jc.2015-4391. Epub 2016 Apr 15. PubMed PMID: 27082933.

56: Hartl DM, Breuskin I, Mirghani H, Berdelou A, D'Andreis D, Pottier E, Borget I, Schlumberger M, Leboulleux S. Anatomic Variability of the Upper Mediastinal Lymph Node Level VII. World J Surg. 2016 Aug;40(8):1899–903. doi: 10.1007/s00268-016-3505-2. PubMed PMID: 27075985.

57: Tacher V, Le Deley MC, Hollebecque A, Deschamps F, Vielh P, Hakime A, Ileana E, Abedi-Ardekani B, Charpy C, Massard C, Rosellini S, Gajda D, Celebic A, Fertè C, Ngo-Camus M, Gouissem S, Koubi-Pick V, Andre F, Vassal G, Deandreis D, Lacroix L, Soria JC, De Baère T. Factors associated with success of image-

guided tumour  
biopsies: Results from a prospective molecular triage study  
(MOSCATO-01). Eur J  
Cancer. 2016 May;59:79-89. doi: 10.1016/j.ejca.2016.02.006. Epub  
2016 Mar 24.  
PubMed PMID: 27017289.

58: Dercle L, Deandreis D, Terroir M, Leboulleux S, Lumbroso J,  
Schlumberger M.  
Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of  
patients with  
differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016  
Jun;43(6):1006-10. doi: 10.1007/s00259-016-3334-4. PubMed PMID:  
26928579.

59: Geraldo L, Ceci F, Uprimny C, Kendler D, Virgolini I. Detection  
of  
Sarcomatoid Lung Metastasis With 68GA-PSMA PET/CT in a Patient With  
Prostate  
Cancer. Clin Nucl Med. 2016 May;41(5):421-2. doi: 10.1097/RLU.  
0000000000001157.  
PubMed PMID: 26859209.

60: Ceci F, Castellucci P, Graziani T, Schiavina R, Renzi R,  
Borghesi M, Di  
Tullio P, Brunocilla E, Ardizzoni A, Fanti S. (11)C-Choline PET/CT  
in  
castration-resistant prostate cancer patients treated with  
docetaxel. Eur J Nucl  
Med Mol Imaging. 2016 Jan;43(1):84-91. doi: 10.1007/  
s00259-015-3177-4. Epub 2015  
Sep 1. PubMed PMID: 26323576.